Novartis closes on filings for oral BTK drug remibrutinib as a treatment for chronic spontaneous urticaria after reporting 52-week data.

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.